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1. Introduction 
Antiretroviral drugs have made a significant impact on HIV/AIDS disease progression and 
have significantly extended the life expectancy of HIV-infected individuals, particularly 
when used in combination therapies such as HAART (highly active antiretroviral therapy). 
However, despite this success, recent reports indicate that HIV morbidity and mortality 
remain at epidemic proportions. It is estimated that over 33 million people are currently 
infected with the virus worldwide, while sub-Saharan Africa accounted for approximately 
70% of all infected individuals and AIDS-related deaths in 2009 (UNAIDS, 2010). Issues of 
drug resistance, drug toxicity, correct patient compliance and the inability to remove latent 
reservoirs of infection remain significant problems to overcome. The need to develop novel 
and improved therapeutic strategies against HIV therefore remains an important medical 
objective. Gene-based therapies hold much promise as alternative treatment strategies for 
HIV/AIDS. Anti-viral gene therapies aim to provide a once-off, long-lasting treatment 
against the virus and thereby address some of the shortcomings associated with current 
antiretroviral therapies. 
A gene therapy against HIV offers several unique advantages, including the sustained 
inhibition of viral replication and the removal of virus from cellular reservoirs. Moreover, by 
improving specificity, the common toxic side effects associated with current antiretrovial 
regimens can be diminished. A number of different RNA-based and protein-based gene 
therapy strategies have been explored and some have reached phase 1 and 2 clinical trials. Our 
research focuses on the development of RNA-based antiviral strategies and in particular, those 
that utilise gene expression strategies based on RNA interference (RNAi). In this chapter, we 
examine basic concepts and review recent advances in the development of expressed RNAi-
based systems against HIV, with a focus on progress in construct and target design. We also 
discuss topics related to the use of RNAi-based strategies, including appropriate construct 
expression, target specificity, viral escape mutations and effective construct delivery. We aim 
to identify desirable properties of an RNAi-based anti-HIV therapy and highlight the future 
developments that are required to make this approach a reality. 
2. RNA interference 
RNA interference (RNAi) is a gene silencing phenomenon in which RNA molecules act to 
silence the expression of particular genes at a post-transcriptional level in the cell. RNAi has 
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become a popular tool in the development of antiviral therapeutics as the potent silencing 
mechanism can be redirected against viral genes to inhibit viral replication. RNAi was first 
described by Fire et. al. (Fire et al., 1998) and has since been demonstrated in a number of 
different organisms including yeast, plants and animals. The mediators of RNAi are short 
21- and 22- nucleotide (nt) RNAs known as small interfering RNAs (siRNAs) or microRNAs 
(miRNAs) and are derived from longer double stranded (ds) RNAs. SiRNAs/miRNAs 
direct the silencing of complementary gene transcripts in a sequence-specific manner. RNAi 
was first described in mammalian cells in 2001 (Elbashir et al., 2001a) and subsequent 
research has moved swiftly to reveal a number of pathway components and mechanisms. 
Mammalian RNAi is now emerging as a complex network with several alternative RNA 
forms and levels of regulatory interactions (Breving and Esquela-Kerscher, 2009); (Ding et 
al., 2009). RNAi–based therapeutics, however, still make use of the central RNAi pathway 
involved in miRNA biogenesis (Figure 1). Our discussion of RNAi-based strategies begins 
here with a description of this major RNAi pathway and how it can be redirected to inhibit 
viral replication. 
The mammalian RNAi pathway mediates gene silencing through the generation of miRNAs. 
MiRNA regulation of genes is both essential and ubiquitous and has been implicated in the 
regulation of developmental timing, cellular differentiation, apoptosis, cell proliferation and 
organ development (Bartel, 2004). MiRNAs are expressed from non-protein-coding genes in 
intergenic or intronic regions as single or polycistronic transcripts by RNA polymerase II 
(Lee et al., 2004); (Cullen, 2004). MiRNA transcripts are usually several kilobases long and 
fold back upon themselves to form characteristic hairpin structures known as primary-
microRNAs (pri-miRNAs) with flanking sequences, a partially duplexed stem and a 
terminal loop. Pri-miRNAs are processed in the RNAi pathway in two successive enzymatic 
steps (Lee et al., 2002b) to produce mature miRNAs from the double-stranded stem region. 
The first processing step occurs in the nucleus where the pri-miRNA is cleaved 
asymmetrically by the “microprocessor” complex to produce a shorter ~ 70 nt hairpin 
known as a precursor-microRNA (pre-miRNA) with a 2 nt overhang at the 3’ hydroxyl end. 
The microprocessor complex includes two essential proteins, namely, the RNAse III enzyme 
Drosha and the DGCR8 (DiGeorge critical region 8) protein (Han et al., 2004). The pre-
miRNA is exported from the nucleus to the cytoplasm by the nuclear karyopherin Exportin-
5 (Exp-5) in a Ran-GTP-dependant manner (Yi et al., 2003); (Lund et al., 2004). In the second 
processing step, the pre-miRNA is cleaved asymmetrically by another RNase III enzyme, 
Dicer (Paddison et al., 2002) to produce staggered ~22 base pair (bp) miRNA/miRNA* 
duplex with 2 nt overhangs at each 3’ hydroxyl end. Dicer is thought to form a complex with 
TRBP (TAR RNA-binding protein) (Chendrimada et al., 2005) and PACT (protein activator 
of protein kinase PKR) (Lee et al., 2006).  
One strand of the miRNA/miRNA* duplex is selected as the mature miRNA or guide 
strand and loaded into the RNA-induced silencing complex (RISC) (Martinez et al., 2002a). 
The guide strand (miRNA) is typically selected from the duplex as a result of weaker 5’ end 
pairing, while the remaining passenger strand (miRNA*) is degraded (Khvorova et al., 2003); 
(Schwarz et al., 2003). In certain cases, both strands of the duplex may be capable of RISC 
incorporation. RISC facilitates sequence-specific gene silencing and is directed by the guide 
sequence to complementary regions in the 3’ untranslated regions of target messenger 
RNAs. RISC-targeting results in the cleavage, degradation or translational suppression of a 








Fig. 1. The mammalian microRNA biogenesis pathway which mediates RNAi. Artificial 
antiviral constructs can be introduced at points 1, 2 and 3 of the pathway and processed to 
inhibit viral replication. 
www.intechopen.com
 
Understanding HIV/AIDS Management and Care – Pandemic Approaches in the 21st Century 
 
196 
target sequence (Hutvagner and Zamore, 2002); (Zeng et al., 2003). Guide strands with near-
perfect complementation tend to mediate cleavage of the target by activating the core catalytic 
Argonaute-2 (Ago-2) protein of RISC. Target cleavage is also a typical characteristic of siRNA-
mediated gene silencing. Most miRNAs exhibit incomplete complementation, resulting in 
translational suppression. Complete complementation, however, is still required for the seed 
region of the miRNA (5’ position 2-7) for effective target knockdown (Brennecke et al., 2005) 
and a single mismatch in this region can prevent silencing (Elbashir et al., 2001b).  
To redirect the RNAi silencing pathway to silence viral genes, artificial anti-viral siRNAs 
and miRNAs can be introduced into the cell to enter different points of the RNAi pathway 
(Figure 1: 1, 2, 3). Antiviral guide sequences are designed to be complementary to viral 
transcripts and can be incorporated into various forms of artificial RNAi intermediates 
including pri-miRNAs, pre-miRNAs, and miRNAs. Once in the pathway, these anti-viral 
intermediates are processed to give therapeutic guide sequences which act to suppress viral 
gene expression and inhibit viral replication. RNAi strategies have been used against 
incoming viral RNA to prevent integration, but it appears as if the strength of RNAi remains 
in its role in post-transcriptionl gene silencing (PTGS). Incoming viral RNA appears to be 
unsuitable for targeting as it is bound by several proteins and transcribed within a short 
time frame, which may limit its susceptibility to RNAi. A number of different antiviral 
constructs and targeting and delivery strategies have been investigated against HIV with 
varying success and are discussed in the following sections. 
3. Antiviral RNAi constructs 
The potential application of RNAi for the treatment of HIV was recognised shortly after the 
first application of RNAi modalities in mammalian cells (Capodici et al., 2002; Coburn and 
Cullen, 2002; Jacque et al., 2002; Lee et al., 2002a; Martinez et al., 2002b). However, it soon 
became apparent that RNAi therapies fall into two broad groups: those that are expressed in 
the cell and those that are not. The basic forms of antiviral RNAi constructs are shown in 
Figure 2. There are specific advantages and drawbacks associated with both synthetic and 
expressed constructs with regard to delivery, duration of inhibition and dose control (Table 
1), but which type of anti-viral construct is best suited for the treatment of HIV?  
3.1 Non-expressed, synthetic RNAi constructs  
Small interfering RNAs (siRNAs) are the most common form of non-expressed RNAi 
constructs. Initial studies of RNAi induction in mammalian cells showed that siRNAs can be 
used as powerful tools for artificial gene silencing. Despite the relative potency of siRNAs, 
their use in a permanent therapeutic application is limited by the lack of continued 
expression (Tuschl and Borkhardt, 2002). Although, this feature can be useful for particular 
applications where topical administration is possible and doses can be more easily 
controlled. An siRNA (ALN-RSV01) against nucleocapsid expression of Respiratory 
Syncytial Virus (RSV) was successfully delivered to healthy individuals in the form of a 
nasal spray in a randomized, double-blind, placebo-controlled clinical trial (Devincenzo et 
al., 2010). The treatment was shown to decrease the number of infected subjects by 38%, 
independently of other factors like pre-existing RSV antibody and intranasal pro-
inflammatory cytokines. While siRNAs may not be suitable for once-off gene therapies, this 








Fig. 2. Various forms of therapeutic constructs used to trigger antiviral RNAi. Each construct 
generates antiviral siRNA or miRNA guide sequences (green, yellow, red and blue) which 
initiate silencing of complementary viral targets. Constructs may be non-expressed or 
expressed in a singular or multiple format (combinatorial-RNAi). 
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No. Therapeutic effects are 
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continuous treatments are 
required. 
Yes. Auto-expression sustains the 
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synthesised. 
Yes, but this is dependent on the type 
of promoter selected. Cell-specific or 




No. SiRNAs are suitable 
substrates for direct association 
with RISC. 
Yes. Anti-viral siRNA/miRNA 
guides must be processed from RNA 




Less likely as processing and 
export enzymes are not utilised. 
A serious concern related to over-
expression of artificial constructs. 
Choice of expression system is 
critical. 
Dose Doses can be more easily 
predicted and controlled as 
construct expression is not a 
factor. 
Exact expression levels under specific 
promoters can only be determined 
empirically and may vary with time 
and genetic background. 
Delivery SiRNAs can be administered 
directly. Chemical 
modifications can be included 
for enhanced absorption or 
targeting to a specific tissue.  
More complex. Viral vectors are often 
used for transduction, but issues with 
safety and efficacy persist. Cell-based 
delivery systems appear promising.  
Table 1. A comparison of non-expressed and expressed antiviral RNAi constructs. 
3.1.1 siRNAs 
SiRNA duplexes have been shown to effectively silence a number of HIV target genes. 
SiRNAs against mRNAs of the Gag protein and CD4 cellular receptor have been shown to 
inhibit post-integrative expression events with a four-fold reduction in viral entry and a  
47 % decrease in p24 expression in HIV cell culture challenge assays (Novina et al., 2002). 
SiRNAs against tat and rev transcripts specifically inhibited protein function and viral 
replication in human T cell lines and primary lymphocytes (Coburn and Cullen, 2002). 
SiRNA duplexes against the long terminal repeat (LTR) and accessory genes vif and nef were 
shown to be effective at inhibiting viral production from infectious molecular clones by 30 to 
50 fold in 24 hours (Jacque et al., 2002). 
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Exogenous siRNAs in the form of duplexes were found to be the most effective at 
redirecting the silencing mechanism against both endogenous and transfected genes 
(Elbashir et al., 2001a), while the characteristic 2 nt overhangs at both the 5’ and 3’ ends are 
an essential feature (Caplen et al., 2001). Artificial siRNAs are selected for RISC 
incorporation more directly and there is no need for Drosha or Dicer processing (Figure 1, 
point 1). This can prevent saturation of the RNAi pathway components and interference 
with the essential miRNA biogenesis. The use of short siRNA duplexes is preferable over 
longer dsRNAs which were previously used, as interferon responses in the cell can be 
avoided. The most effective synthetic siRNA duplexes are designed to be about 19 – 21 nts 
in length with 3’ overhangs, but it has also been shown that shorter siRNAs of only 16 nts 
may trigger more potent RNAi as a result of higher RISC-loading capacity(Chu and Rana, 
2008). 
The chemical synthesis of siRNA duplexes is conceptually simple, as are the methods of 
electroporation, microinjection and liposome-mediated transfections for siRNA introduction 
into cells. The continuous need for these methods in large-scale siRNA use, however, can 
become labour-intensive. Coupled with the transient nature of siRNA-induced gene 
silencing (maximum ~ 1 week), the advantages of an expressed siRNA construct in 
therapeutic applications are clear. Nevertheless, novel delivery mechanisms for synthetic 
siRNAs have been developed for HIV. Specifically, studies in humanized mouse models of 
HIV using anti-gp120 aptamer-siRNA chimeras have demonstrated their potential as 
specific antiviral agents (Neff et al., 2011); (MacRae et al., 2008); (Zhou and Rossi, 2010). 
Similarly, siRNAs conjugated to single-chained monoclonal antibody fragments targeted to 
T-cell or lymphocyte-specific receptors have shown promise in vivo (Kim et al., 2010; Kumar 
et al., 2008). However, these methods are in the earlier stages of development and there are 
still several delivery and potency hurdles which must be overcome. The focus of this review 
will be on expressed RNAi modalities, where siRNA duplexes are expressed from plasmid 
DNA vectors with lasting effects on gene silencing.  
3.2 Expressed RNAi constructs 
SiRNAs that are generated from expression cassettes have the advantage of sustained 
production which makes them suitable for long-term, once-off therapeutic applications. 
Recent developments in construct design and delivery methods have shown much promise 
for the advancement of siRNA expression systems against HIV. In earlier siRNA expression 
studies, linear cassettes were constructed to code for both sense and antisense sequences of 
the siRNA duplex under the control of separate promoters and termination signals (Lee et 
al., 2002a); (Miyagishi and Taira, 2002). Expressed siRNAs then associate post-
transcriptionally to form a duplex with 2 – 4 nt uridine overhangs. This system was found to 
be effective against HIV-1 sequences and siRNAs targeting a highly-accessible region of the 
rev transcript were found to inhibit viral transcript expression (Lee et al., 2002a). However, 
the reliability of correct siRNA duplex association in vivo is questionable. Most siRNA 
expression constructs are now designed to generate mimics of RNAi intermediates in the 
form of siRNA or miRNA hairpin precursors which are processed by Drosha and/or Dicer 
enzyme complexes (Figure 2). This is preferable for more reliable siRNA processing in a 
manner that is regulated by the RNAi pathway, but inappropriate expression levels can lead 
to saturation of critical RNAi components.  
The choice of promoter is therefore critical in achieving suitable levels of construct 
expression. Polymerase III (pol III) promoter sequences, like human U6 snRNA (small 
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nuclear RNA U6) or H1 (human RNAse P H1), are commonly used to drive efficient 
expression of short downstream sequences and often feature in short hairpin expression 
cassettes. They have been well characterised in earlier ribozyme expression studies (Good et 
al., 1997) and are suitable to drive nuclear expression in a wide range of human cell types (Paul 
et al., 2002). However, the high level of constitutive expression from pol III promoters can be 
undesired in a long-term therapeutic treatment. Polymerase II (pol II) promoters, like the 
human cytomegalovirus (CMV) promoter, are now being favoured for lower and potentially 
regulatable expression of pri- and pre-mRNA mimics. They allow for safer tissue-specific 
expression of constructs with tighter in vivo regulation (Cullen, 2005); (Giering et al., 2008). 
Other types of inducible promoters have also been investigated for regulated expression in the 
presence of an activator molecule (Jacque et al., 2002), which would satisfy the need for greater 
control of construct expression in therapeutic applications.  
3.2.1 Short hairpin RNAs 
Short hairpin RNAs (shRNAs) were developed for the expression of siRNA duplexes (Paul et 
al., 2002). ShRNAs are essentially mimics of precursor-miRNAs that are processed by Dicer to 
produce staggered siRNA duplexes. ShRNAs typically have short, completely complementary 
stem regions of about 19 -29 base pairs (bp), a 2 nt 3’ overhang and one of several commonly 
used terminal loops. Synthetic shRNAs have been shown to trigger more effective gene 
silencing than siRNA duplexes with the same guide sequences (Siolas et al., 2005). The 
association of shRNAs with Dicer may result in more effective loading of guide sequences 
onto RISC, as Dicer forms part of the RISC-loading complex (RLC) (MacRae et al., 2008).  
A variety of different guide sequences can be expressed from shRNAs. Sequence 
composition of individual guides can affect the processing efficiency, but common shRNA 
formats generally give high levels of expression. An shRNA against the HIV-1 transactivator 
(Tat) protein gene was incorporated into an H1-driven expression cassette and delivered to 
cells through the use of a recombinant AAV (adeno-associated virus) DNA vector (Boden et 
al., 2003). In a cell culture challenge assay with the infectious molecular clone HIV-1NL4.3, 
HIV-1 p24 antigen levels were decreased by 97% 48 hours post-transfection in cells 
expressing the shtat compared to control cells. The high mutability of HIV, however, 
severely hinders the potency of silencing by a single shRNA in a long-term application. In 
cells stably expressing shtat, HIV-1 replication was reduced by 95% in the first three weeks, 
but had again risen by day 25 as a result of a nonsynonymous mutation in the targeted 
region. 
The silencing efficacy of an shRNA mostly depends on the level of conservation of the HIV 
target sequence and shRNAs with equal processing do not necessarily result in the same level 
of HIV inhibition. ShRNAs against the viral integrase sequence (shIN) and the U3 region of the 
viral genome required for integration (shU3) showed a more potent inhibitory effect on HIV-1 
replication than shtat in shRNA-transduced MT-4 or primary CD4_ T cells (Nishitsuji et al., 
2006). In p24 viral replication assays, shint produced a ~ 4 fold reduction in p24 production, 
while shtat resulted in a ~2.5 fold reduction four days post-infection. In contrast, a similar 
hairpin against the U5 region of the viral genome resulted in weak inhibition, possibly due to 
high GC content. At 10 days postinfection, viral replication was again detected in the shTat-
transformed MT-4 cells, while HIV-1 replication was undetectable for up to 1 month 
postinfection, in cells that received shIN or shU3. While this is an improvement, the use of 
single shRNAs is still unsuitable for long-term HIV suppression. 
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The choice of stem and loop structures must also be carefully considered in shRNA design. 
A completely duplexed stem assists in preserving shRNA structure and can be useful for the 
prevention of 3’ – 5’ exonuclease attack (Paul et al., 2002), but is not a necessity and the high 
level of duplex stability may also interfere with strand selection. While typical stem lengths 
of about 19 bp are effective, longer 29 bp stems can be more potent triggers of RNAi with 
more effective processing, suggesting that Dicer requires a minimum stem length for 
efficient cleavage (Siolas et al., 2005). Loop sizes are more variable and can be anywhere 
between 3 and 9 nts in size. A recent investigation has confirmed that loop sequences are 
indeed critical in determining shRNA function against HIV-1 sequences (Schopman et al., 
2010). ShRNAs with sub-optimal loop sequences (Brummelkamp et al., 2002) can be slightly 
altered to increase RNA activity by up to 7 fold. The size of optimal loops appears to be 
between 7 and 10 nts, while decreasing loops to 5 nts or less appears to be detrimental to 
RNAi activity. Particular loop structures, especially those derived from pri-miRNAs, can 
enhance processing of weak shRNAs. The importance of loop structure may be attributed to 
Dicer co-factors, like the KH-type splicing regulatory protein (KSRP), which binds to the 
terminal loop and affects processing (Vermeulen et al., 2005); (Trabucchi et al., 2009) . 
Pol III promoters like U6 or H1 are well suited for the constitutive expression of shRNAs in 
a range of cell types. The pol III termination signal consists of a short stretch of uridine 
residues which are cleaved at the termination site after two residues. This is ideal for the 
generation of a 3’ UU overhang in the hairpin, which is important for the efficiency and the 
specificity of siRNA processing by Dicer. Robust shRNA expression from pol III promoters 
can be detrimental for a therapeutic application. High levels of sustained expression can 
lead to cytotoxicity and even to a lethal saturation of the RNAi pathway. The long-term 
effects of robust shRNA expression were investigated in the livers of adult mice and found 
to cause liver injury, organ failure and death within one month (Grimm et al., 2006). 
Morbidity was associated with the downregulation of natural liver miRNAs, which 
suggested that competition exists for components of the RNAi pathway such as Exportin-5. 
In a more recent publication, Ago-2 (Slicer) was identified as the primary rate-limiting 
determinant of both in vitro and in vivo RNAi efficacy, toxicity, and persistence (Grimm et 
al., 2010). Ago/shRNA coexpression studies have shown that increased Ago-2 and Exp-5 
expression can rescue long-term U6-driven shRNA expression in adult mice with enhanced 
silencing of exogenous and endogenous hepatic targets, reduced hepatotoxicity, and 
extended RNAi stability of more than 3 months. The benefits of using a weaker promoter 
were demonstrated in this study where in vivo toxicity was alleviated, allowing for 
sustained target silencing of over a year. Overall, shRNAs are very potent gene-silencing 
moieties, but their safe and effective use in anti-HIV gene therapies is dependent on 
appropriate promoter and target selection. 
3.2.2 Mimics of microRNA precursors 
There seem to be several advantages in creating antiviral constructs with properties that are 
similar to endogenous miRNA precursors. This includes the incorporation of mismatches 
into the stem region, the use of longer stems and different terminal loops. Enhanced 
silencing has been observed for siRNAs derived from hairpins based on precursor–miRNAs 
(pre-miRNAs). SiRNAs against the HIV-1 tat gene were placed into the natural pre-miR-30 
backbone and found to be 80% more effective at reducing HIV replication than the same 
guide expressed from a conventional shRNA (Boden et al., 2004). Hairpins based on 
primary-microRNAs (pri-miRNAs) with pol II promoters have also been shown to induce 
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potent, stable and regulatable gene silencing in vivo, even when present as a single copy in 
the genome (Dickins et al., 2005). These pri-miR mimics have been described as second-
generation shRNAs and termed shRNA-miRs (Silva et al., 2005). 
Artificial miRNAs not only show a greater inhibitory efficacy against HIV targets when 
compared to conventional shRNAs (Liu et al., 2008), but may also be better at suppressing 
imperfect HIV-1 targets (Liu et al., 2009a). This enhanced silencing ability has been 
attributed to more efficient processing in the RNAi pathway by both Drosha and Dicer 
enzyme complexes. Pri-miRNA mimics may also be subjected to regulatory mechanisms 
and other important components of the RNAi pathway, unlike substrate mimics introduced 
further on in the pathway (Obernosterer et al., 2006). In addition, there may be functional 
differences between RISC-siRNA and RISC-miRNA with respect to Ago protein association.  
As might be implied from nature, it is necessary to maintain several key elements of natural 
pri-miRNA structures for effective processing of artificial miRNAs. It has been suggested 
that a large terminal loop (≥ 10 nts), a stem between 26 and 40 bp and at least 40 nts of non-
structured flanking RNA sequences are required for efficient processing by Drosha (Zeng et 
al., 2005). Single-stranded flanking sequences may form part of the Drosha-RNA interface 
(Zeng and Cullen, 2005) and it seems logical to preserve the natural flanking sequences in 
the use of miRNA precursors as scaffolds. Preservation of natural loop sequences also 
appears to be desirable and has been shown to rescue the inhibitory potential of weakly 
functioning shRNAs (Schopman et al., 2010).  
In comparisons of the silencing ability of shRNA and artificial microRNA constructs with 
similar guide strands,  shRNAs were generally found to produce a more potent silencing 
effect (Boudreau et al., 2008). This has, however, been attributed to a higher level of 
expression both in vivo and in vitro. As already discussed, higher expression of shRNAs is 
undesirable in a therapeutic setting. Artificial miRNAs with a lower expression are 
processed more efficiently in the RNAi pathway and cause less of a bottleneck which can 
lead to saturation toxicity. SiRNAs expressed from a microRNA backbone do not appear to 
show the same level of inhibitory competition for nuclear export by Exportin-5 and 
incorporation into RISC (Castanotto et al., 2007). Pri-miRNA mimics therefore appear to be 
safer option for therapeutic use and show less disruption of natural microRNA biogenesis 
(Boudreau et al., 2009). Pri-miRNAs, however, do not show consistent processing over a 
range of different guide sequences, as can be observed for shRNAs. Pri-miRNAs therefore 
appear to be a more favourable expression format for siRNAs, but sufficient processing of 
guide sequences must be assessed empirically.  
3.3 Combinatorial RNAi constructs 
Despite the potency of RNAi against HIV targets in short-term studies, the sustained 
inhibition of viral replication is not possible with a single siRNA construct. Viral escape 
mutations arise readily in response to the strong selective pressure of effective RNAi 
constructs.  SiRNAs directed against the viral nef gene and introduced into human T cells by 
retroviral transduction successfully inhibit viral replication at first, but after several weeks 
of culture RNAi-resistant viruses developed (Gregory et al., 2004). Viral mutations included 
nucleotide substitutions or deletions in the Nef gene that modified or deleted the siRNA-Nef 
target sequence. Similarly, expressed shRNAs targeting the HIV-1 tat gene soon give rise to 
a viral quasispecies harbouring a point mutation in the shRNA target region which 
abolishes antiviral activity of tat shRNA (Boden et al., 2003). Silent mutations in protein-
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coding sequences can also occur. Viral escape mutations are, however, not limited to point 
mutations in the siRNA target sequences. Mutations can occur in other regions of the 
genome that alter the local RNA secondary structure of the target site and diminish siRNA 
binding (Westerhout et al., 2005).  
The key to successful HIV inhibition lies in the targeting of several highly conserved regions 
simultaneously in a combinatorial approach (co-RNAi). This strategy has been used in a 
number of conventional drug regimens and aims to reduce the emergence of viral escape 
mutants by inhibiting multiple HIV targets. Expressed shRNA and shRNA-miR constructs 
can be adapted to produce multiple siRNAs and combined in single plasmid vectors. RNAi 
constructs can also be more easily adapted than small molecules in response to viral 
evolution. Several studies have investigated viral mutation pathways in response to 
particular therapeutic stimuli in order to identify and block anticipated escape paths. 
Interestingly, viral escape paths against shRNA therapy differ to those triggered by drug 
therapy (Applegate et al., 2010). 
3.3.1 Multiple short hairpin RNAs  
Multiple short hairpins can be used against HIV simply through the use of multiple vectors 
or through the design of consecutive shRNA constructs. The simultaneous use of two 
separate hairpins against the CCR5 and CXCR4 cellular receptors has been shown to protect 
transduced primary macrophages against HIV infection (Lee et al., 2003). The consistent 
delivery and expression of two separate shRNAs in an equal ratio is not precise using a 
simultaneous approach and multiple shRNA constructs are preferable for more controlled 
expression levels. A bi-specific construct containing a U6-driven shRNA against CXCR4 and 
an H1-driven shRNA against the CCR5 has been shown to effectively downregulate both 
targets simultaneously (Anderson and Akkina, 2005). When the siRNA expressing 
transduced cells were challenged with X4 and R5 tropic HIV-1, they demonstrated marked 
viral resistance. Targeting of three different HIV regions is even more favourable for 
effective coRNAi and has been demonstrated using a multi-shRNA construct. Three H1-
driven shRNAs against two pol and one gag sequence were successfully used to create an 
additive inhibition of viral production and delay viral escape (ter Brake et al., 2006).  
Combining multiple shRNAs with the same construct structure can be problematic. The use 
of repeated promoter sequences can lead to rearrangements and deletions of whole 
transcriptional units as a result of recombination in lentiviral delivery vectors. To prevent 
this, non-identical pol III promoters U6, H1, and 7SK and the polymerase II U1 promoter 
can be used to drive simultaneous expression in a multi-shRNA cassette which can inhibit 
HIV without viral escape (ter Brake et al., 2008). However, equivalent expression of each 
siRNA is not guaranteed and high expression levels of several anti-viral guides still occurs 
which can lead to even more serious saturation toxicity (McIntyre et al., 2009). ShRNAs, 
even in a multiple format, are therefore not necessarily the most preferable expression 
systems for therapeutic applications. 
3.3.2 Long hairpin RNAs 
To avoid issues associated with the toxicity of multiple promoter-driven constructs, 
several adjacent siRNA sequences can be incorporated into single long hairpin constructs 
(lhRNAs) under the control of one promoter. Consecutive Dicer cleavage is required 
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along the length of the hairpin to release individual siRNA duplexes (Paddison et al., 
2002). A modified long hairpin against a 50 nt region of the integrase gene effectively 
suppressed both wild-type and shint-resistant viral strains (Nishitsuji et al., 2006). A U6-
driven long hairpin RNA spanning a possible 60 bp of a 5’LTR target region has shown 
silencing of respective target sequences and inhibition of HIV replication (Barichievy et al., 
2007). The greatest silencing in this format was observed for the target corresponding to 
the base of the hairpin stem.  
In a more pre-meditated approach, several well-characterised shRNA sequences can be 
concatenated into a single long or extended shRNA (e-shRNA). E-shRNAs were designed 
with two siRNAs against nef and pol HIV-1 sequences which were efficiently processed and 
showed viral inhibition (Liu et al., 2007). The position of the two siRNAs was found to be 
critical for the generation of functional siRNAs. In a further step, the generation of three 
siRNAs from a single U6-driven hairpin was investigated against tat, rev and vif (Saayman et 
al., 2008). All sequences were capable of target silencing depending on their position within 
the hairpin and processing efficiency decreased from the stem of the hairpin towards the 
terminal loop. Spacing between the siRNA sequences within the duplex stem region can 
also affect processing efficiency. E-shRNAs can be extended to include a maximum of 3 
siRNAs with an optimal length of 66 bp. Further stem extension results in a loss of RNAi 
activity (Liu et al., 2009a). A size limit of 80 bp has also been suggested and the incorporation 
of G:U wobbles may have several advantages related to hairpin expression (Sano et al., 
2008).  
A further advancement which circumvents the length limitation of lhRNAs is the use of a 
long hairpin concatenation. A recent study has shown that four functional anti-HIV siRNAs 
can be derived from a single Pol III-generated transcript comprising two adjacent long 
hairpin RNA precursors (Saayman et al., 2010). Two active anti-HIV siRNAs were 
engineered into each of two lhRNAs, which were arranged in tandem to create a double 
long hairpin (dlhRNA) expression cassette. Each hairpin component was found to generate 
two of four unique siRNA sequences (tat, nef, LTR and int) and thereby mediate dual-
targeting. Processing of the individual siRNAs was found to be affected by both internal 
ordering and spacing between siRNAs. An inverse correlation between siRNA silencing 
potency and increased spacing was observed, while processing at the 3’ position of each 
lhRNA was more variable. Optimal siRNA processing was found to occur when only one 
mismatched base pair was placed between each siRNA in accordance with predicted Dicer 
cleavage intervals. Effective multiple processing was achieved by manipulating the order of 
the siRNA-encoding sequences to create an optimized combinatorial dlhRNA expression 
cassette. Despite the use of a pol III promoter, expression potency of the individual guides is 
diluted and therefore less likely to cause toxic saturation. This work has highlighted the 
versatility of dlhRNAs and shown that they are a promising construct form for effective 
silencing of multiple HIV targets.  
3.3.3 Polycistronic primary microRNA mimics 
Safe and controlled expression of siRNAs is a particular concern in coRNAi. Once again, a 
logical way of doing this is to mimic mammalian microRNA expression systems. MiRNAs 
are often expressed as pol II-driven polycistronic units in the cell and multiple siRNAs can 
be expressed in a similar fashion. In some systems, effective singular miRNA mimics, like 
those based on the pri-miR30 backbone, were simply incorporated in tandem under the 
control of a single pol II promoter to express two or three artificial guides (Han et al., 2006) 
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(Ely et al., 2009). Different pri-miRNA backbones have different expression aptitudes for 
individual sequences and the ordering of pri-miRNA expression units can affect both 
expression and silencing abilities. The preservation of natural pri-miRNA structural 
elements is still required in multiple constructs with a minimum of 22 nt of natural flanking 
sequence required at the 5′ arm and at least 15 nt at the 3′ arm (Zeng and Cullen, 2005). In 
addition to this, extra restriction sequences must often be included to create the tandem 
format. This can be very useful for creating modular pri-miRNA units that can be exchanged 
as required. On the other hand, extra artificial and repetitive natural flanking sequences in 
the expressed transcript can interact in an unexpected fashion to form undesirable 
secondary structures which prevent or alter processing of the intended guide sequences.  
Multiple guide sequences can be incorporated into other natural miRNA precursor forms. In 
an earlier example, the BIC non-coding RNA with its embedded miR-155 miRNA precursor 
was used as a scaffold for construction of the SIBR vector (Chung et al., 2006).  Synthetic 
miRNA sequences were incorporated into a modified miR-155 stem-loop, along with 
flanking sequences from the third exon of the BIC transcript, which proved to be sufficient 
for the expression of miR-155. It was found that two artificial miRNAs could be expressed 
from a single polycistronic transcript to give effective inhibition of targets without a 
decrease in the efficacy of individual target suppression. Alternatively, up to 8 tandem 
copies of the same artificial miRNA can be expressed from the SIBR vector in tandem for 
enhanced expression, but this is not a favourable option for HIV inhibition where strong 
silencing of a single target should be avoided.  
A simpler approach for polycistronic design is to mimic entire naturally occurring 
polycistronic pri-miRNA units. Multiple effective siRNAs can be inserted into a naturally 
occurring polycistronic scaffold and expressed from a single promoter sequence. The mir-
17-92 polycistron has been successfully used as a scaffold for four siRNAs against rev/tat, 
gag, pol and leader HIV sequences (Liu et al., 2008). In this example, each siRNA sequence 
was initially incorporated into an individual pri-miRNA structure with about 40 nts of 
flanking sequences and assessed. In doing so, the passenger strand was altered with the use 
of predictive secondary structure software to maintain all mismatches, bulges and 
thermodynamic stability as far as possible. Positioning of guide sequences in each pri-
miRNA hairpin was found to be crucial for optimal processing. Individual hairpins showed 
moderate anti-HIV activity, but co-expression of two or more hairpins in a polycistronic 
format gave greatly enhanced silencing from each individual pri-miRNA component. 
Antiviral siRNAs have also been engineered into the tri-cistronic miR-106b cluster (Aagaard 
et al., 2008) to produce 3 siRNAs against tat/rev, tat and rev.  In both of these examples, 
polycistronic expression systems appear to have an intrinsic inhibitory activity greater than 
that of conventional shRNA constructs or individual hairpins. 
In all examples of mimic design, it appears that the preservation of key structural elements 
is crucial for effective processing and inhibitory function. Although the predictive software 
for this purpose is of a very high standard, folded structures and sequence interactions in 
vivo can never be guaranteed. This is of particular concern when modular pri-miRNA units 
are being combined in a novel way. Guide sequence expression from pri-miRNA mimics is 
also variable and can depend on both the anti-viral sequence and backbone used. 
Transposition of 19 nt siRNAs from shRNA expression systems into pri-miRNA units can be 
tricky as miRNA sequences can be up to 24 nts in length. Only one guide can be used per 
pri-miRNA hairpin, which means that combinatorial constructs will inevitably contain quite 
a lot of extra, non-guide sequence. Construct size can be a limiting factor for insertion into 
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viral vectors, but polycistronic pri-miRNA units are still generally within an acceptable size 
range. In general, the use of pri-miRNA mimics requires more planning and testing of 
individual components, while the final construct behaviour can only really be observed 
experimentally. This makes polycistronic miRNA expression systems more labour intensive, 
but thorough testing should be part of any therapeutic strategy. The extra input may be well 
worthwhile if the potential advantages of combined HIV targeting at an appropriate 
expression level with regulated and efficient processing can be realised.  
3.3.4 Therapeutic constructs 
Overall, it appears as if dlhRNAs or polycistronic mimics appear to possess the best 
combinations of desirable properties for a therapeutic RNAi application. Developments are, 
however, still required before these constructs can be implemented in a clinical setting. 
Expression systems can be further optimised to give restricted expression in target cell 
populations and therefore reduce the risk of unwanted off target effects (OTEs). More 
specific expression can be achieved through the use of a haematopoietic or T-cell-specific 
promoter (Liu et al., 2008). The WAS promoter, for example, is active in human 
hematopoietic precursor cells (CD34+), T lymphocytes, B cells and dendritic cells, but not in 
non-haematopoietic cells and may be an excellent candidate (Charrier et al., 2007). 
Expression could ideally be further restricted to HIV infected cells by using the HIV-1 LTR 
promoter to express the miRNA polycistron only in the presence of the viral Tat protein 
(Unwalla et al., 2004). Furthermore, RNAi activators are probably best used in combination 
with other types of RNA- or protein-based anti-HIV constructs in a therapeutic application 
to mediate an even more potent viral inhibition that does not rely on a single genetic 
mechanism. A polycistronic miRNA mimic, for example, can be combined with a TAR 
decoy for enhanced viral inhibition. ShRNAs can also be applied therapeutically in 
combination with other RNA-based constructs, for example, an anti-CCR5 ribozyme and a 
TAR decoy for greater protection against from HIV-1 challenge (Wilson et al., 2003). It 
therefore seems that the best therapeutic approaches involve the use of combinations of both 
RNAi triggers and different types of inhibitory mechanisms, while maintaining natural 
RNAi processing and overall cellular function as far as possible.  
4. RNAi target selection 
A critical factor in the success of any RNAi-inducing therapeutic strategy is the choice of 
target sequence. Highly effective therapeutic effectors can be rendered ineffective in a 
clinical setting if careful consideration is not given to the long-term targeting strategy. 
SiRNAs have been designed against most regions of HIV-encoded RNAs,  including tat, rev, 
gag, pol, nef, vif, env, vpr, and the long terminal repeat (Figure 2). However, there is no single 
Achilles heel in the HIV genome and targeting of several highly conserved regions across 
multiple viral strains is a requirement for a clinically relevant RNAi-based therapy. In silico 
approaches for target identification are therefore crucial, although targeting strategies must 
still be experimentally validated. 
Highly conserved HIV sequences are rare. In an extensive study of siRNA target prediction for 
optimal design of siRNAs, highly conserved sequences were analysed from the Los Alamos 
HIV Sequence Database covering 495 divergent strains of subtype M (Naito et al., 2007). Of the 
4 million potential 21-mer siRNA target sites, only 5.2 % showed a level of conservation 
greater than 50%. Highly conserved (> 80%) siRNA target sequences are very rare (< 1 %) and 
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only about 14 % of these rare potential sites correspond to functional siRNA predictions. This 
finding has called for serious reconsideration of the clinical potential of numerous previous 
studies which generally target regions outside of this highly conserved category. 
Highly conserved target sites are essential in a therapeutic application to successfully inhibit 
mixed and fluctuating viral populations. Ideal target regions of the HIV genome include 
essential regulatory regions of viral gene expression. Among these are the primer activation 
signal (PAS), primer binding site (PBS), packaging signal (), central polypurine tract 
(cPPT), central termination sequence (CTS) and 3’ polypurine tract (3’ PPT). These regions 
are conserved at the nucleotide sequence level, presumably to conserve secondary RNA 
structures which are important for viral fitness. Other highly conserved potential siRNA 
target sites include the packaging signal, TAR/polyA and regions in protease and integrase 
protein codes. It does not seem possible for a single siRNA to target all known HIV-strains, 
but this work by Naito et. al. suggests that it is theoretically possible to target >99% of 
circulating subtype M strains with escape resistance by combining only two siRNAs against 
highly conserved viral sequences.  
In other previous studies, it has been suggested that four conserved sequences will be 
sufficient to inhibit several hundred circulating viral stains (Leonard and Schaffer, 2005). It is, 
however, unlikely that sequences across several viral strains will harbour sufficient sequence 
identity to be effectively targeted by the same set of four shRNAs. It has since been proposed 
that more than four shRNAs should be utilised in therapeutic design such that each viral strain 
will be effectively targeted by at least four shRNAs (McIntyre et al., 2011). ShRNA 
combinations of seven H1-driven expression units were found to provide up to 87% coverage 
for all known HI V strains and 100% coverage of clade B subtypes. Position within a specific (1 
– 7) multi-shRNA cassette generally had little effect on the suppressive activity of individual 
shRNAs when expressed in isolation, but when shRNA expression was simultaneous, 
expression decreased for shRNAs in position 3 – 7. The effective and equal expression of 6 or 7 
tandem shRNAs is a challenge and the use of so many pol III promoter units poses a 
substantially higher risk of toxic saturation of the endogenous RNAi pathway. However, the 
possibility of inhibiting multiple viral strains simultaneously is a tempting motivation for 
further development of both multi-shRNA and larger polycistronic mimic expression systems.  
As an alternative to highly mutable viral sequences, host dependency factors (HDFs) 
encoded by the cell can also be targeted to further inhibit viral replication. The CD4 receptor 
required for viral entry is an obvious choice, but is also present on other host cells in which 
silencing of CD4 may result in undesirable side-effects. The CCR5 and CXCR4 co-receptors 
are more attractive targets for silencing and have been investigated (Novina et al., 2002, Song 
et al., 2003). There are however many other host factors involved in HIV replication, such as 
those required for Tat binding to TAR (cyclin T1 and CDK9) and those that bind to the LTR 
to control gene expression (NF-κB, SP1, LBP, and LEF).  SiRNAs against the NF-κB p65 
subunit resulted in decreased viral replication (Surabhi and Gaynor, 2002). Large screen 
studies have also revealed numerous other potential targets (Brass et al., 2008). Cellular 
targeting is promising, but must be used with caution as the inhibition of cellular proteins 
can have widespread effects on cellular function with undesirable side effects.  
5. Safety & toxicity of RNAi activators 
A primary concern with the use of RNAi-based strategies is that of safety and the specificity 
of the inhibitory effect in vivo. The presence of double stranded RNA (dsRNA) can activate 
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cellular defence mechanisms which lead to a non-specific halt in translation and cell death. 
DsRNA induces an interferon type 1 (IFN-1) response in the cell which in turn activates the 
transcription of other immune effector molecules, IFN stimulated genes (ISGs) and Dicer-
related pathways (de Veer et al., 2005); (Karpala et al., 2005). DsRNA can also activate the 
retinoic-acid inducible gene-I (RIG-I) and members of the oligoadenylate synthetase (OAS) 
receptor family which catalyze the synthesis of 2’-5’ oligoadenylates to activate a latent 
cellular endoribonuclease (RNASEL), which in turn cleaves cellular and viral mRNAs. A 
key effector molecule is the dsRNA-responsive protein kinase receptor (PKR) which 
functions to block translation of both viral and cellular proteins. PKR activation is typically 
induced by long dsRNA molecules (>30 nts), but can also be induced by exogenously 
introduced short 19–29 nt dsRNAs. SiRNAs and shRNAs can induce an IFN response in 
cells through toll-like receptors (TLRs), particularly TLR3 (Kariko et al., 2004). Ironically, 
these immune responses play a role in viral defense systems of the cell, but can create issues 
for the introduction of artificial anti-viral constructs. However, siRNA sequences tend to be 
only weak inducers of the IFN response and the use of siRNA expression systems can be 
effective in avoiding an immune response (Robbins et al., 2006).  
Another major concern with RNAi activators is the unintentional suppression of cellular 
transcripts with partial sequence complementation described as off-target effects (OTEs). As 
the seed region (position 2-7 nt) is the most crucial determinant of target specificity, it seems 
probable that several cellular transcripts will be susceptible to such a short region of 
sequence complementation. Some microarray studies have shown that even targets with one  
or two base pair mismatches with an siRNA  can be affected (Jackson et al., 2003). The use of 
multiple guide sequences is required for effective long-term viral inhibition, but this 
increases the number of potential OTEs. In a number of studies, cellular toxicity has not 
been observed, suggesting that OTEs may not necessarily have a significant impact on 
cellular function (Liu et al., 2008). Nonetheless, extensive attempts should be made to predict 
potential OTEs before clinical application.  
Saturation of the endogenous RNAi pathway with highly expressed RNAi-activators, like 
pol III-driven shRNAs, can have potentially lethal toxic side effects (Grimm et al., 2006). As 
already mentioned, polycistronic pri-miRNA mimics can be useful in avoiding competition 
with the components of the pathway through reduced expression levels and more regulated 
processing of guide sequences. The natural properties of these mimics may also be useful in 
avoiding immune stimulation and careful target selection may reduce unwanted OTEs. 
Although, the complete reduction of OTEs is unlikely and extensive screening of in vivo cell 
expression patterns may be the only real way to assess the extent of undesirable effects.  
6. RNAi towards the clinic 
A number of RNAi-based effectors have reached clinical trials, but safe and effective 
expression and delivery of RNAi constructs remains an obstacle for most therapeutic 
approaches. Recent developments have shown much promise in addressing common 
delivery issues. Novel nanotechnologies have been used for the delivery of exogenous 
siRNAs (Davis et al., 2010), while lentiviral vectors that are stably transduced with an 
extended hairpin expression cassette have been shown to durably inhibit HIV-1 in T-cells 
(Liu et al., 2009b). Finer details of lentiviral optimisation are now being elucidated and it 
seems that unique strategies are required for shRNA and miRNA expressing vectors 
(Schopman et al., 2010).  
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Cell-based delivery appears to be the most promising approach for the development of a 
realistic therapeutic strategy (Figure 3). Essentially, haematopoietic stem cells (HSCs) are 
collected from suitable donor candidates and transduced ex vivo with anti-HIV expression 
constructs. Lentiviral vectors are preferable for this purpose as they can mediate integration 
of therapeutic constructs into the cellular genome even in non-dividing cells for long-term 
construct expression (Naldini et al., 1996). Transduced HSCs are then infused into an HIV-
infected patient where they can give rise to HIV-resistant cell populations. This method 
allows for controlled transduction of target cell populations where aberrant integrative 
events may be detected and eliminated ex vivo.  
Cell-based delivery may involve allogeneic or autologous cell transplantation. In a pivotal 
allogeneic study, replicating HIV remained undetected in a recipient patient 20 months after 
transplantation and termination of HAART (Hutter et al., 2009). In this case, HSCs were 
obtained from a donor homozygous for a naturally occurring HIV-resistant phenotype and 
successfully transplanted into an HIV-infected patient with acute myeloid leukemia 
following myeloablative therapy. Cells with the Δ32CCR5 mutation harbour a 32 bp 
deletion in the gene for chemokine receptor 5 and are protected from infection by R5-tropic 
viral subtypes. This strategy proved to be effective for treating leukaemia and preventing 
viral replication. Notorious HIV-reservoirs, like the intestinal lamina propria, remained HIV 
free 159 days after transplantation. While this approach seems ideal for effective HIV 
inhibition in vivo, homozygous donors for the CCR5 mutation are rare, occurring in only ~ 
1% of the white population. Nonetheless, this promising strategy can be adapted for the 
delivery of HSCs with an artificial HIV-resistant genotype.  
Autologous cell–based approaches do not require matching of HLA genotypes and avoid 
the host-versus-graft complications. In a recent RNA-based example, a ribozyme (OZ1) 
against the tat-vpr region of the HIV genome was delivered to patients through transduced 
autologous CD34+ hematopoietic progenitor cells (Mitsuyasu, 2009). Progenitor cells were 
transduced with a murine retroviral vector encoding the OZ1 ribozyme. The cell-delivery 
method was assessed through a randomised, double-blind, placebo-controlled phase 2 gene 
transfer clinical trial with 74 HIV-1 infected individuals. The OZ1 group showed 
significantly lower viral loads after 40 weeks and  significantly higher CD4+ lymphocyte 
counts through 100 weeks. This study demonstrated that cell-delivered gene transfer can be 
both a safe and effective therapeutic strategy.  
In a more recent clinical trial, three RNA-based anti-HIV constructs were introduced into 
patients undergoing transplantation for AIDs-related lymphoma (DiGiusto et al., 2010). HIV-
infected individuals represent a unique and ethically-sound research group where marrow 
ablation can be performed prior to transplantation. A tat/rev short hairpin, TAR decoy and 
CCR5 ribozyme combination construct was used to modify the patient’s own CD34+ cells 
through lentiviral transduction. Transduced cells showed no difference in haematopoietic 
potential compared to non-transduced cells in in vitro analysis and were successfully 
engrafted in four patients. Expression of the anti-HIV moieties was initially as high as 22 %, 
but declined to ~1% over four weeks of cell culture. Persistent siRNA expression was 
observed at low levels for up to 24 months in multiple lineages. No short-term toxicity was 
associated with the infusion of the genetically modified cells, and observed toxicities were 








Fig. 3. An overall scheme for an RNAi-based therapy against HIV. SiRNAs or expressed 
RNAi constructs are delivered to infected cells by direct or vector-mediated methods 
This study has demonstrated a viable approach for effective therapeutic expression of 
RNAi-based constructs against HIV-1. Persistent, constitutive shRNA expression over 24 
months was not found to be toxic to peripheral blood cells and there was no evidence for 
lineage-specific toxicity. An artificial, anti-HIV expression vector can therefore be stably 
expressed in human blood cells without significant toxic side effects. The method of ex vivo 
lentiviral transduction and autologous cell-based gene transfer has been demonstrated as a 
safe and effective means of construct expression. The long term inhibitory effect on viral 
replication and evolution in the absence of anti-retroviral drugs remains to be seen. The 
demonstration of sustained anti-viral siRNA expression, however, has moved us one step 
closer to the realisation of a clinically applicable once-off treatment against HIV-1 infection. 
Further improvements in transduction and transplantation procedures are likely to yield 
even more favourable results for the therapeutic application of RNAi.  
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A genetic approach using expressed RNAi modalities offers the possibility of a once-off 
treatment against HIV with permanent and sustained viral inhibition and without common 
toxic side effects associated with current drug regimens. In this chapter, we have discussed 
the pros and cons of several RNAi-inducers that can be used to inhibit HIV replication. To 
summarise, an ideal RNAi-based gene therapy against HIV will make use of a combination 
of effective siRNA sequences in a single expression vector against at least four, but 
preferably six or seven, highly conserved viral target sequences or host dependency factors. 
This will provide potent silencing of target sequences across all known viral strains and 
prevent the emergence of viral escape mutants. Each siRNA sequence needs to be expressed 
at an equivalent and appropriate level under the control of a regulatable or HIV-inducible 
pol II promoter to avoid biased targeting and prevent the toxic and potentially lethal 
competition-based saturation of the natural RNAi pathway. The use of polycistronic pri-
miRNA mimic expression systems appears most favourable and the preservation of natural 
structural motifs appears to enhance processing and silencing capabilities, as well as avoid 
activation of the innate immune system, which may otherwise occur with the introduction 
of exogenous constructs. Off-target effects should be modelled as far as possible before 
therapeutic testing and should be limited to non-significant effects. The most suitable 
delivery method to date appears to be through autologous cell-based gene transfer 
transplantation in a myeloablated recipient background with ex vivo lentiviral transduction 
of the patient’s own haematopoietic progenitor cells. This is quite a comprehensive list of 
desirable properties for an ideal RNAi-based therapy against HIV and is the result of 
intensive research over the past decade. Further developments are necessary for the 
realisation of a safe and effective genetic therapy against HIV, but in light of the research 
presented here, we are moving closer. 
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